Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus

Current Medical Research and Opinion

Volumn 25, Issue 12, 2009, Pages 3049-3057

  Seino, Yutaka ^a   Nakajima, Hiromu ^b   Miyahara, Hajime ^b   Kurita, Takashi ^b   Bush, Mark A ^c   Yang, Fred ^c   Stewart, Murray W ^c  

^a KANSAI ELECTRIC POWER CO   (Japan)

^b Development and Medical Affairs Division   (Japan)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Albiglutide; GLP 1; Incretin; Japanese; Type 2 diabetes mellitus

Indexed keywords

ALBIGLUTIDE; C PEPTIDE; GLUCAGON; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; INSULIN;

ABDOMINAL PAIN; ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIET RESTRICTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG FATALITY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; FEMALE; FLATULENCE; GASTROINTESTINAL SYMPTOM; GLUCAGON BLOOD LEVEL; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INCIDENCE; INJECTION SITE REACTION; INSULIN BLOOD LEVEL; JAPANESE; MALE; MULTICENTER STUDY; NAUSEA; NON INSULIN DEPENDENT DIABETES MELLITUS; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; SINGLE BLIND PROCEDURE; TREATMENT DURATION; UPPER RESPIRATORY TRACT INFECTION; VITAL SIGN; VOMITING;

ADULT; AGED; ALGORITHMS; ASIAN CONTINENTAL ANCESTRY GROUP; DELAYED-ACTION PREPARATIONS; DIABETES MELLITUS, TYPE 2; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; PLACEBOS; RECEPTORS, GLUCAGON; SINGLE-BLIND METHOD;

EID: 72549107810     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990903372999     Document Type: Article

References (27)

1. International Diabetes Federation. Diabetes Atlas. 2006. Available at: http://www.eatlas.idf.org/webdata/docs/background-opening-pc.pdf [Last accessed 23 March 2008]
2. Katakura M, Komatsu M, Sato Y, et al. Primacy of β-cell dysfunction in the development of hyperglycemia: a study in the Japanese general population. Metabolism 2004;53:949-953 (Pubitemid 38829473)
3. Fukushima M, Usami M, Ikeda M, et al. Insulin secretion and insulin sensitivity at different stages of glucose intolerance: a cross-sectional study of Japanese type 2 diabetes. Metabolism 2004;53:831-835 (Pubitemid 38829453)
4. Nauck MA, Kleine N, Orskov C, et al. Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients. Diabetologia 1993;36:741-744 (Pubitemid 23218642)
5. Nauck MA, Wollschläger D, Werner J, et al. Effects of subcutaneous glucagon- like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM. Diabetologia 1996;39:1546-1553
6. Zander M, Madsbad S, Madsen JL, et al. Effect of 6-week course of glucagonlike peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 2002;359:824-830 (Pubitemid 34233752)
7. Farilla L, Hui H, Bertolotto C, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinol 2002;143:4397-4480 (Pubitemid 35239574)
8. Amori RE, Lau J, Pittas AG. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007;298:194-206 (Pubitemid 47057766)
9. Nauck MA, Duran S, Kim D, et al. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. Diabetologia 2007;50:259-267
10. Heine RJ, Van Gaal LF, Johns D, et al. for the GWAA Study Group. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes. Ann Int Med 2005;143:559-569
11. Buse JB, Henry RR, Han J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. Diabetes Care 2004;27:2628-2635 (Pubitemid 39441462)
12. Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care 2005;28:1083-1091 (Pubitemid 40616617)
13. DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005;28:1092-1100 (Pubitemid 40616618)
14. Klonoff DC, Buse JB, Neilsen LL, et al. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. Curr Med Res Opin 2008;24:275-286
15. Marre M, Shaw J, Brandle M, et al. Liraglutide, a once-daily human GLP-1 analog, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1-SU). Diabetic Med 2009; 26:268-278
16. Nauck M, Frid A, Hermansen K, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes mellitus (LEAD-2 Met). Diabetes Care 2009;32:84-90
17. Garber A, Henry RR, Ratner R, et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase 3, double-blind, parallel-treatment trial. Lancet 2008;373:473-481
18. Russell-Jones D, Vaag A, Schmitz O, et al. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. Diabetologia 2009;52:2046-2055
19. Buse JB, Rosenstock J, Sesti G, et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009;374:4-6
20. Kadowaki T, Namba M, Yamamura A, et al. Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. Endocrine J 2009;56:415-424
21. Seino Y, Rasmussen MF, Zdravkovic M, et al. Dose-dependent improvement in glycemia with once-daily liraglutide without hypoglycemia or weight gain: a double-blind, randomized controlled trial in Japanese patients with type 2 diabetes. Diabetes Res Clin Pract 2008;81:161-168
22. Baggio LL, Huang Q, Brown TJ, et al. A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis. Diabetes 2004;53:2492-2500 (Pubitemid 39145610)
23. Matthews JE, Stewart MW, De Boever EH, et al. Pharmacodynamics, pharmacokinetics, safety and tolerability of albiglutide, a long-acting GLP-1 mimetic, in patients with type 2 diabetes. J Clin Endocrinol Metab 2008; 93:4810-4817
24. Bush MA, Matthews JE, DeBoever EH, et al. Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagonlike peptide-1 mimetic, in healthy subjects. Diabetes Obes Metab 2009;11:498-505
25. Rosenstock J, Reusch J, Bush M et al.; for the Albiglutide Study Group. The potential of albiglutide, a long-acting GLP-1-receptor agonist, in type 2 diabetes: a randomized controlled trial exploring weekly, biweekly, and monthly dosing. Diabetes Care 2009;32:1880-1886
26. Shirai K. Evaluation of obesity and diagnostic criteria of obesity as a disease for Japanese. [in Japanese] Nippon Rinsho 2001;59:578-585
27. Wajchenberg BL. β-cell failure in diabetes and preservation by clinical treatment. Endocr Rev 2007;28:187-218 (Pubitemid 46984834)